<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290498</url>
  </required_header>
  <id_info>
    <org_study_id>2005-0054</org_study_id>
    <secondary_id>NCI-2012-01355</secondary_id>
    <nct_id>NCT00290498</nct_id>
  </id_info>
  <brief_title>Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger</brief_title>
  <official_title>A Phase II Randomized Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this clinical research study was to find out which of two different
      chemotherapy drug combinations, R-CHOP and R-HCVAD, is more effective in treating B-cell
      lymphoma.

      At this point, all participants will now be assigned to the R-HCVAD arm of the study.
      Researchers will study the safety and effectiveness of this drug combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study originally involved 2 different study drug regimens, R-CHOP and R-HCVAD. R-CHOP is
      made up of rituximab, cyclophosphamide, vincristine, and prednisone, and is the most common
      treatment for patients with non-Hodgkin's lymphoma. This combination was compared with
      R-HCVAD, which is made up of rituximab, doxorubicin, cyclophosphamide, vincristine, and
      dexamethasone.

      Rituximab (RituxanÂ®) is a humanized monoclonal antibody against cluster of differentiation
      antigen 20 (CD20) (a receptor in the surface of malignant B-cell lymphocytes). The drug has
      activity against aggressive and nonaggressive NHL of B-cell origin, and has been used in
      combination with chemotherapy. Cyclophosphamide is a type of drug know as an alkylating
      agent. Vincristine is a type of drug called vinca alkaloids. It is typically used in
      lymphomas, leukemias, and other tumors. Prednisone is a type of steroid. Dexamethasone is a
      steroid that may have activity against lymphomas. Methotrexate is an anti-cancer drug and a
      folic acid antagonist. It is used to treat solid tumors, lymphomas, leukemias, and autoimmune
      diseases.

      When this study began, participants were randomly assigned (as in the flip of a coin) to 1 of
      2 arms: Arm A (R-HCVAD alternating with a combination of rituximab, methotrexate, and Ara-C)
      or Arm B (R-CHOP). From this point on, all new participants will be treated with the Arm A
      combination, which has shown to be better.

      If you are found to be eligible to take part in this study, you will be given the study drugs
      in 21-day cycles. The cycles will alternate between R-HCVAD and a combination of rituximab,
      methotrexate, and Ara-C. During Cycle 1 (the R-HCVAD cycle), you will receive rituximab
      through a needle in your vein (intravenously, or &quot;IV&quot;), on Day 1. The infusion will take
      about 1 hour. Cyclophosphamide will be given by IV every 12 hours for 3 days. Each infusion
      of cyclophosphamide will take about 3 hours. Doxorubicin will be given as a 15-minute
      infusion on Day 5 with the supervision of a nurse. Your doctor may also choose to give you
      the doxorubicin over 24-48 hours using a small pump that you will carry around your waist in
      a &quot;fanny pack.&quot; You will not have to stay in the hospital to receive this study drug.
      Vincristine will be given by IV, on Days 5 and 12. Each vincristine infusion will take about
      an hour. Dexamethasone will be given by mouth (as a pill, capsule, or tablet) on Days 2-5 and
      12-15. You will also be given other standard medications to help prevent possible side
      effects of these medications (such as nausea, vomiting, or rash).

      In Cycle 2 (the rituximab-methotrexate-Ara-C cycle), you will receive rituximab on Day 1. You
      will receive methotrexate by IV (after finishing the rituximab) on Days 2 and 3. The infusion
      will take about 24 hours. You will be given a small &quot;fanny pack&quot; with a pump inside that will
      slowly infuse the drug. You do not have to stay in the hospital while the drug is being
      given. You will be given Ara-C every 12 hours on Days 3-4 (a total of 4 doses). You will be
      given other standard medications to help prevent possible side effects of these medications
      (such as nausea, vomiting, or rash) during this cycle also.

      Leucovorin is given 12 hours after each methotrexate infusion. It is used to stop the action
      of the methotrexate and to prevent/lessen any side effects that the methotrexate may cause.

      During treatment, you will have blood draws (between 2-3 tablespoons) every week for routine
      tests. Every 4 weeks during treatment , you will be asked questions about your medical
      history and have a physical exam to check for any side effects. Every 2 cycles (about every 8
      weeks), you will have bone marrow biopsies performed (if they were positive before starting
      on this study), until they come back negative. You will have a positron emission tomography
      (PET) scan to see if the tumor is responding. Once the PET scan comes back negative, it will
      be up to your physician to decide if you need additional PET scan tests, and when. You will
      have CT scans of the chest, abdomen, pelvis, and neck every 2 cycles, if they were positive
      at the beginning of the study also. You may have additional testing done while on this study,
      if your physician feels that it is needed (for example, if it is needed to check for side
      effects).

      You may receive additional medication called &quot;CNS prophylaxis&quot; before receiving the study
      treatments. Your doctor will discuss these medications with you. The &quot;CNS prophylaxis&quot;
      consists of an alternating dose of either doxorubicin or methotrexate. The methotrexate will
      be given either by IV pump or by a &quot;lumbar puncture&quot; (a needle inserted into the space
      between the vertebrae in your back to infuse the drug directly into the spinal area). The
      doxorubicin will be given by IV. Changes in the dose level of CNS prophylaxis will be
      approved if you are at risk for or are experiencing serious side effects.

      You will receive the study drugs for up to 6-8 cycles on an outpatient basis. This means you
      will not have to be admitted to the hospital to receive the study drugs. You may be taken off
      study if the disease gets worse. If you experience intolerable side effects while taking any
      of the study drugs, your study doctor may decide to delay your treatment for up to 3 weeks
      (one study cycle) or to continue your therapy on the drugs at a lower dose. If the side
      effects become very severe, your doctor may decide to take you off of the study and stop the
      medication.

      At the end of your scheduled treatments, you will be asked to return to the clinic for
      follow-up visits every 6 months for the first, second, third, and fourth year after treatment
      on this study. You will then be followed every year after that. If your doctor feels it is
      necessary, you may have blood tests (about 3-5 teaspoons) performed at these visits. You will
      have bone marrow biopsies every other year for the first 2 years, if they were positive
      before you started on this study, and then every year after that. At these visits, you will
      be asked about any side effects you may have experienced and whether or not your cancer has
      come back. If your doctor feels there is a chance that the cancer has come back, he or she
      may schedule x-rays or scans in order to check. You will also be asked about any other
      therapies you may be having to treat your cancer, if it has come back.

      If you are taken off study for any reason, you will be asked to come back to the clinic for
      an end-of-treatment visit within 4 weeks from the last treatment. This visit will include a
      physical exam, routine blood tests (about 5-8 teaspoons), a blood-pregnancy test for women
      who are able to get pregnant, an ECG, and a chest x-ray.

      This is an investigational study. All of the study drugs are approved by the FDA for the
      treatment of lymphoma. Up to 66 patients will take part in this study. All of the patients
      will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2005</start_date>
  <completion_date type="Actual">August 11, 2017</completion_date>
  <primary_completion_date type="Actual">August 11, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate R-HCVAD vs. R-CHOP</measure>
    <time_frame>3 years</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (Rate)</measure>
    <time_frame>3 years post-therapy</time_frame>
    <description>Progression free survival (PFS) for three years following therapy with Rituxan-HCVAD alternating with Rituximab with high -dose methotrexate/ara-C and standard R-CHOP in patients with newly diagnosed B-cell aggressive non-Hodgkin's lymphomas younger than 60 years old and with adjusted IPI 2 or higher adverse prognostic features.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R-HCVAD + R-MTX/Ara-C ((Rituximab-HCVAD (rituximab, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) alternating with Rituximab-Methotrexate-Cytarabine))</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>R-CHOP ((Rituximab-CHOP (Rituximab, cyclophosphamide, vincristine, and prednisone))
No longer recruiting for this study arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Arm A: Rituximab 375 mg/mÂ² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/mÂ² on day 1, Cycle 2 and alternating cycles.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Arm A: Cyclophosphamide 300 mg/m^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.
Arm B: Cyclophosphamide 750 mg/mÂ² by vein day 1</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Arm A: Doxorubicin 50 mg/m^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>AD</other_name>
    <other_name>Hydroxydaunomycin hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Arm A: Vincristine 1.4 mg/m^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.
Arm B: Vincristine 1.4 mg/m^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Arm B: Cytarabine 3 g/m^2 by vein over 2 hours every 12 hours X 4 doses on days 3 &amp; 4, cycle 2 and alternating cycles.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine arabinosine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of previously untreated large B-cell Non Hodgkin's, Large Cell
             Lymphoma and B-Cell with high grade features. Other aggressive lymphomas such as
             Primary Mediastinal large B-cell Lymphomas will be also allowed to be included.

          2. Patients with performance status of 0-2 (Zubrod Scale).

          3. Serum bilirubin &lt;1.5 mg/dl and serum creatinine &lt; 2.0 mg/dl unless due to lymphoma;
             absolute neutrophil count (ANC) &gt;1000/mm^3 and platelets &gt;100,000/mm^3 unless due to
             lymphoma.

          4. Cardiac ejection fraction 50% or greater.

          5. Ages 16 - 60 years (due to the fact that CHOP-R is not studied enough in younger
             patients and is not considered standard of care).

          6. Patients must be willing to receive transfusions of blood products.

          7. Age adjusted International Prognostic Index Score of 2 or more

          8. Previous steroids are allowed (if used to relieve some symptoms such as SVC, etc).

        Exclusion Criteria:

          1. Pregnancy (excluded due to the teratogenicity of the involved chemotherapy agents

          2. Positive HIV serology because of poor tolerance to this intense chemotherapy regimen

          3. Burkitt's lymphomas, and Mantle cell lymphoma, transformed follicular center cell
             lymphoma, follicular grade III.

          4. Any clinical or cytological diagnosis of central nervous system (CNS) involvement

          5. Any co-morbid medical, such as Child's Class C liver cirrhosis, end-stage renal
             disease, and symptomatic congestive heart failure, or psychiatric illnesses that
             preclude treatment with intense dose chemotherapy as determined by the primary
             investigator.

          6. Concurrent or previous malignancy whose prognosis is poor (&lt; 90% probability of
             survival at 5 years)

          7. Active Hepatitis B or C. Chronic carriers for Hepatitis B will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis E. Fayad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 10, 2006</study_first_submitted>
  <study_first_submitted_qc>February 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2006</study_first_posted>
  <results_first_submitted>December 10, 2019</results_first_submitted>
  <results_first_submitted_qc>May 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 2, 2020</results_first_posted>
  <last_update_submitted>May 18, 2020</last_update_submitted>
  <last_update_submitted_qc>May 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>B-Cell Non-Hodgkin's Lymphoma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Hyper-CVAD</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Vincristine</keyword>
  <keyword>R-CHOP</keyword>
  <keyword>R-HCVAD</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Decadron</keyword>
  <keyword>Leucovorin</keyword>
  <keyword>Ara-C</keyword>
  <keyword>Cytosar</keyword>
  <keyword>Cytoxan</keyword>
  <keyword>DepoCyt</keyword>
  <keyword>Cytosine arabinosine hydrochloride</keyword>
  <keyword>AD</keyword>
  <keyword>Hydroxydaunomycin hydrochloride</keyword>
  <keyword>Neosar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 17, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT00290498/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient eligibility:&gt;/16 -&lt;/60 years old and untreated Diffuse Large B-cell Lymphoma,stage II &gt;/10cm mass or stage III/IV),Eastern Cooperative Oncology Group 0-2,age-adjusted Integrated Pulmonary Index of .2, and adequate organ function. Excluded:if they were pregnant,breast-feeding,or evidenced central nervous system lymphoma or active infections.</recruitment_details>
      <pre_assignment_details>Three participants were screen failures. Eight participants were removed</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>R-HCVAD-MA</title>
          <description>I.V. rituximab 375mg, cyclophosphamide 300mg, doxorubicin 50mg &amp; vincristine 1.4mg - 2mg, &amp; oral dexamethasone 40mg. Alternate R-MA: IV rituximab 375mg, methotrexate 200mg &amp; 800mg 22h, &amp; cytarabine 3g.</description>
        </group>
        <group group_id="P2">
          <title>R-CHOP</title>
          <description>R-CHOP: Day 1 I.V. rituximab 375mg, cyclophosphamide 750mg, doxorubicin 50mg, vincristine 1.4mg max 2mg, and oral prednisone 100mg orally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>R-HCVAD/R-MA</title>
          <description>I.V. rituximab 375mg, cyclophosphamide 300mg, doxorubicin 50mg &amp; vincristine 1.4mg - 2mg, &amp; oral dexamethasone 40mg. Alternate R-MA: IV rituximab 375mg, methotrexate 200mg &amp; 800mg 22h, &amp; cytarabine 3g.</description>
        </group>
        <group group_id="B2">
          <title>R-CHOP</title>
          <description>R-CHOP: Day 1 I.V. rituximab 375mg, cyclophosphamide 750mg, doxorubicin 50mg, vincristine 1.4mg max 2mg, and oral prednisone 100mg orally.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" spread="11"/>
                    <measurement group_id="B2" value="39" spread="11"/>
                    <measurement group_id="B3" value="42.5" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate R-HCVAD vs. R-CHOP</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-HCVAD</title>
            <description>I.V. rituximab 375mg, cyclophosphamide 300mg, doxorubicin 50mg &amp; vincristine 1.4mg - 2mg, &amp; oral dexamethasone 40mg. Alternate R-MA: IV rituximab 375mg, methotrexate 200mg &amp; 800mg 22h, &amp; cytarabine 3g.</description>
          </group>
          <group group_id="O2">
            <title>R-CHOP</title>
            <description>R-CHOP: Day 1 I.V. rituximab 375mg, cyclophosphamide 750mg, doxorubicin 50mg, vincristine 1.4mg max 2mg, and oral prednisone 100mg orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate R-HCVAD vs. R-CHOP</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inevaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Remission Unconfirmed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (Rate)</title>
        <description>Progression free survival (PFS) for three years following therapy with Rituxan-HCVAD alternating with Rituximab with high -dose methotrexate/ara-C and standard R-CHOP in patients with newly diagnosed B-cell aggressive non-Hodgkin's lymphomas younger than 60 years old and with adjusted IPI 2 or higher adverse prognostic features.</description>
        <time_frame>3 years post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>R-HCVAD/MA</title>
            <description>I.V. rituximab 375mg, cyclophosphamide 300mg, doxorubicin 50mg &amp; vincristine 1.4mg - 2mg, &amp; oral dexamethasone 40mg. Alternate R-MA: IV rituximab 375mg, methotrexate 200mg &amp; 800mg 22h, &amp; cytarabine 3g.</description>
          </group>
          <group group_id="O2">
            <title>R-CHOP</title>
            <description>R-CHOP: Day 1 I.V. rituximab 375mg, cyclophosphamide 750mg, doxorubicin 50mg, vincristine 1.4mg max 2mg, and oral prednisone 100mg orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (Rate)</title>
          <description>Progression free survival (PFS) for three years following therapy with Rituxan-HCVAD alternating with Rituximab with high -dose methotrexate/ara-C and standard R-CHOP in patients with newly diagnosed B-cell aggressive non-Hodgkin's lymphomas younger than 60 years old and with adjusted IPI 2 or higher adverse prognostic features.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the initiation of the regimen until the end of chemotherapy, an average of 3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>RHCVAD</title>
          <description>Rituximab 375mg/m2 intravenously on day 1,cyclophosphamide 300mg/m2 intravenously every 12 h for six doses on days 13,doxorubicin 50mg/m2 intravenously on day 5,vincristine 1.4mg/m2 or maximum 2mg intravenously on days 5 and 12,and dexamethasone 40mg intravenously or orally on days 25,alternating with RMA(cycles 2,4,6,)rituximab 375mg/2 intravenously on day 1,methotrexate 200mg/m2 over 2 h followed by 800mg/m2 over 22 h on day 1, and cytarabine 3g/m2 every 12 h for four doses on days 3 and 4, with a 21 day cycle.</description>
        </group>
        <group group_id="E2">
          <title>RCHOP</title>
          <description>RCHOP consisted of rituximab 375mg/m2 intravenously on day 1,cyclophosphamide 750mg/m2 intravenously on day 1,doxorubicin 50mg/m2 intravenously on day 1 either over 15min or 48 h , vincristine 1.4mg/m2 or maximum 2mg intravenously,and prednisone 100mg orally on days 15,with a 21d cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>BLOOD BONE MARROW (OTHER)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PETECHIAE</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PERICARDIAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>AUDITORY/EAR (OTHER)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>ENDOCRINE (OTHER)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>BLURRED VISION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>OCULAR/VISUAL(OTHER)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (EYE)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>WATERY EYE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL CRAMPING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DISTENSION/BLOATING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL (OTHER)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HEARTBURN</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>OBSTRUCTION,GI</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (ABDOMEN NOS)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (ANUS)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN( ORALCAVITY)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN( STOMACH)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>TASTE ALTERATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>TEETH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>DEATH NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DRUG FEVER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>EDEMA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>EDEMA:HEAD AND NECK</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>EDEMA:LIMB</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>EDEMA:TRUNK/GENITAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>EDEMA (LARYNX)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>FEVER UNKNOWN ORIGIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>FEVER WITHOUT NEUTROPENI</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>FLU-LIKE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>GAIT/WALKING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (DENTAL/TEETH/PERID</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (NOS)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>RIGORS/CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC REACTION DRUG</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ALLERGY (OTHER)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>AUTOIMMUNE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>INFECTION(S)</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>BRUISING (NON-THROMBOPENIA)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALKALINE PHOSPHATASE INCR</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ALT,SGPT INCR</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>AST,SGOT INCR</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>BILIRUBIN INCREASE</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>CHOLESTEROL,SERUM-HIGH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>CREATININE INCREASE</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ELEV LDH (OTHER)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>GRANULOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HEMOGLOBIN DECREASE</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPERKALEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPERURICEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINEMIA</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPOCALCEMIA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPOGLYCEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPOKALEMIA</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESEMIA</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPONATREMIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>OLIGURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PLATELETS DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DIABETES</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>METABOLIC/LABORATORY (OTHER)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>WEIGHT GAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>WEIGHT LOSS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCLE WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>MYOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (BACK)</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (BONE)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (EXTREMITY-LIMB)</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (JOINT)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (MUSCLE)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (NECK)</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (PELVIS)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>COGNITIVE DISTURBANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>MEMORY IMPAIRMENT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>NEUROPATHY:MOTOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>NEUROPATHY:SENSORY</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN( HEAD/HEADACHE)</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (NEURALGIA/PERIPHERALNER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>SENSORY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>SYNCOPE (FAINTING)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>MOOD ALTERATION</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>POLYURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>URINARY FREQUENCY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>HOT FLASHES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (BREAST)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (TESTICLE)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (VAGINA)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>VAGINAL DRYNESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ALLERGIC RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DYSPNEA</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HORSENESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>MUCOSITIS</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (CHEST/THORAX)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (PLEURITIC)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PAIN (THROAT/PHARYNX/LARYNX)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PULMONARY(OTHER)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>RHINORRHEA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>SORE THROAT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY INFECT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>VOICE CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY/SKIN (OTHER)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ERYTHEMA MULTIFORME</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HAND-FOOT SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HYPERPIGMENTATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PRURITUS/ITCHING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>RASH/DESQUAMATION</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>SWEATING</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>ULCERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>HEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>SYNDROMES (OTHER)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>THROMBOSIS/THROMBUS/EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>VASCULAR (OTHER)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE 4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/Embolism</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Luis E. Fayad / Lymphoma/Myeloma</name_or_title>
      <organization>U.T. MD Anderson Cancer Center</organization>
      <phone>7137922860</phone>
      <email>lefayad@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

